Biopharmaceutical company Amgen (AMGN) is set to announce its fourth quarter earnings results on Tuesday, February 4th, after ...

Amgen Inc (NASDAQ:AMGN)., a leading biopharmaceutical company with a market capitalization of $155 billion, is at a pivotal juncture as it navigates the competitive landscape of innovative ...

Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a complex landscape of opportunities and challenges as it positions itself ...

Amgen is a biotechnology leader with competitive advantages in scale, R&D, manufacturing efficiency, and distribution, bolstered by a robust pipeline and rising margins. I currently rate Amgen as ...

Amgen stock skidded late Tuesday after the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...

global head of development for Sandoz Biopharmaceuticals. Amgen company is seeking to defend its osteoporosis franchise with UCB-partnered Evenity (romosozumab), an anti-sclerostin antibody that ...

All of a sudden, Amgen stock is up 15% since late December to around $299. Its rise helped push up the healthcare sector up just over 7% since hitting a bottom in late December. The better-than ...

MariTide Phase 3 studies to begin in first half of year FDA places hold on AMG 513 obesity drug trial Amgen's Q4 earnings beat estimates, revenue up 11% Feb 4 (Reuters) - Amgen (AMGN.O), opens new ...

Free cash flow surged to $4.4 billion, up a remarkable 1,367% year over year. Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Request To Download Free Sample of This Strategic Report @ Highlighted with 78 tables and 119 figures, this 215-page report ?Global Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what ...

Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...